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Background: Patients with primary ciliary dyskinesia (PCD) have abnormal ciliary function and
low nitric oxide levels. Nitric oxide (NO) biosynthesis is dependent on nitric oxide synthases
(NOS). Cilia line the bronchial but not the alveolar epithelium. It has been hypothesised that
NOS function relies on normal ciliary function and that in PCD bronchial but not alveolar NO
might therefore be reduced. The aim of this study was to assess bronchial and alveolar NO
levels primarily comparing healthy children to PCD and secondarily to cystic fibrosis (CF)
and asthmatic children.
Methods: Multiple flow-rate fractional exhaled and nasal NO measurements were performed
using a NIOX Flex NO analyser (Aerocrine, Sweden) in children with PCD (nZ 14), asthma
(nZ 18), CF (nZ 12) and healthy controls (nZ 18). Alveolar and bronchial NO levels were
derived using a model of pulmonary NO exchange-dynamics.
Results: Both the bronchial and alveolar NO were significantly lower in PCD than healthy
controls (mean (SD) 264 (209) picolitres/second (pl/s) vs. 720 (514) pl/s, p Z 0.024 and
1.7 (0.8) parts per billion (ppb) vs. 3.5 (1.3) ppb, pZ 0.001 respectively.) In asthmatics bron-
chial NO was found to be significantly higher than in healthy controls and in children with CF
alveolar NO was significantly lower (2100 (1935) pl/s, pZ 0.045 and 2.5 (1.2) ppb, pZ 0.034
respectively.)Experimental Sciences Academic Unit (Mail Point 803), University of Southampton Faculty of Medi-
NHS Foundation Trust, Tremona Road, Southampton SO16 6YD, UK. Tel.: þ44 (0) 23 80796160.
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Nitric oxide in PCD, CF and asthma 381Conclusion: Our findings do not support the hypothesis that NOS and ciliary function are
coupled instead suggesting a more generalised mechanism for the low levels of NO seen in
PCD. Our findings in CF and asthma corroborate evidence that these are diseases of the lung
peripheries and bronchi respectively.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
Nitric oxide is a key cellular signalling molecule, involved in
diverse physiological and pathophysiological processes such
as vascular homeostasis, immune cell activity and broncho-
motor tone.1 It is synthesized in the respiratory epithelium
from L-arginine by three NO synthase isoforms (NOS).2
Infection and inflammation lead to inducible NOS stimula-
tion and henceNObiosynthesis.2 AirwayNO, can bemeasured
using simple non-invasive techniques via the reaction of NO
with ozone and subsequent detection by chemiluminescence
through commercially available equipment.3 This allows
measurement of nasal NO (nNO) and fractional exhaled NO,
typically measured at a flow rate of 50 ml/s (FeNO50).
Primary ciliary dyskinesia (PCD) is an autosomal recessive
condition inwhich abnormal ciliary structure and/or function
lead to impaired mucociliary clearance, recurrent sino-
pulmonary infection and, ultimately, bronchiectasis.4 Nasal
NO and, to a lesser extent, FeNO are characteristically low in
PCD, somuch so that nNO is used as a screening test for PCD in
many specialist centres.5 Abnormal NO concentrations have
been identified in a number of other respiratory diseases
including cystic fibrosis (CF), where NO levels are reduced
compared to healthy controls but not to the degree seen in
PCD and asthma where airway levels are elevated.6,7
Localising the relative contributions of different areas of
the lung to total FeNO levels in these conditions would
increase our understanding of the underlying pathophysi-
ology, potentially providing a useful non-invasive marker for
disease progression, and possibly help to tailor therapies. A
two-compartment model of pulmonary NO exchange
dynamics, usingFeNOmeasurements at several differentflow-
rates, allows estimates of the relative contribution of the
bronchial (J’awNO) and alveolar (CalvNO) areas of the lung to
total FeNO.
8,9 Bronchial NOflux is calculated as the product of
the bronchial wall NO concentration and the NO diffusing
capacity of the airway.9 The alveolar NO concentration is
calculated as a steady NO source, a balance between locally
biosynthesised and inhaled NO vs NO diffusion away.8,9
The raised NO levels seen in asthma are attributed to
eosinophilic inflammation however, it is unclear why NO is
low in PCD and CF despite persistent airway infection and
inflammation.10 A number of potential mechanisms for the
extremely low NO in PCD have been proposed (reviewed in
Ref. 11) however, to date, the actual mechanism(s) remains
elusive. Several papers have hypothesised that it may result
from a reliance of normal NOS activity, and hence NO
biosynthesis, on normal ciliary ultrastructure and/or func-
tion due to a mechano-chemical coupling to dynein ATPases
in the ciliary axoneme.12,13 If this hypothesis were correct
one would expect bronchial NO to be reduced in PCD, as
cilia are present in the bronchial compartment and ciliary
function is impaired in PCD. However cilia are not present
in the alveolar compartment, so alveolar NO should not beaffected by impaired ciliary function and might be
comparable with healthy controls.
The three studies that have used this two-compartment
model in PCD patients to date have conflicting results, but
varied in age and demographics of participants and NO analy-
sers used.13e15 We are the first single study to assess the rela-
tive contributions of the bronchial and alveolar compartments
of the lung to total FeNO, comparing healthy children to those
with PCD and secondarily to children with CF and asthma.
Methods
This study was approved by Southampton and South West
Hampshire Research Ethics Committee (A). REC numbers:
06/Q1702/109 and 08/H0502/126. All subjects gave written
informed consent.
Participants
Children with PCD (nZ 14), asthma (nZ 18) and CF (nZ 12)
patients were recruited from specialist PCD and paediatric
respiratory clinics. Healthy children (nZ 18) recruited from
non-respiratory clinics completed a short questionnaire to
exclude disease that might affect nitric oxide levels. PCD
was diagnosed by assessing the ciliary beat frequency and
pattern of airway epithelial cells by high-speed video
microscopy in patients with a suggestive history. Diagnosis
was further supported by assessment of ciliary ultrastruc-
ture by transmission electron microscopy and, in some
cases, analysis of re-differentiated cilia following culture of
the airway epithelial cells at an air liquid interface.4 CF
diagnosis was based on compatible history, an abnormal
sweat test and/or CF genotyping. Asthma diagnosis was
based on clinical history and characteristic spirometry with
reversibility.16 Children with asthma were on different
British Thoracic Society asthma management steps: step 1
(nZ 1), step 2 (nZ 2), step 3 (nZ 7), step 4 (nZ 5), step 5
(nZ 3).16 CF, asthma and healthy children were age and sex
matched to the participants with PCD.
For inclusion the children had to be over 6 years of age and
be well on the day of testing with no evidence of respiratory
tract infection in the previous four weeks. They were
excluded if they had multiple respiratory diagnoses, had
smoked in the last year or had undertaken spirometry in the
previous hour. We also assessed 14 healthy adults in order to
optimise themethods (data shown in Supplementary Table 1).
Measurement of airway nitric oxide
Measurement of nasal and lower airway nitric oxide levels
using a chemiluminescent NO analyser, NIOX Flex (Aerocrine,
Sweden) followed American Thoracic Society/European
Respiratory Society (ATS/ERS) recommendations.17
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manoeuvre to close the velum whilst a nasal probe sampled
gas aspirated from the nostril at a rate of 5 ml/s. Patients
were encouraged to hold each breath for approximately
20 s until the analyser recorded a plateau in nitric oxide
concentrated from the aspirated gas. Three measurements
were obtained from each child using the same nostril and
the mean nNO reading was recorded.
FeNO was measured at multiple flow-rates (50, 100, 200
and 250 ml/s) whilst maintaining a constant exhalation
pressure >5 cm H20 through visual feedback. Two consis-
tent readings (within 10%) were obtained at each flow-
rates. Calculation of CalvNO (ppb) and J’awNO (nl/min)
were based on the mathematical model of pulmonary NO
exchange dynamics proposed by Tsoukias & George9:
V0NOZVE CalvNO þ J0awNO
Where NO elimination (V’NO) (nl/s) is the exhaled NO
concentration (ppb)  flow rate (V’E) (ml/s), J’awNO (pl/s)
is bronchial NO flux, and CalvNO (ppb) is the steady-state NO
concentration in alveolar air. Therefore the gradient and
intercept of a regression line on a graph of NO elimination
(V’NO) against flow-rate (V’E) represent CalvNO and J’awNO
respectively (Fig. 1).8,9
Spirometry was measured, following NO measurement,
in respiratory participants using a Master Screen Body
(Jaeger) in accordance with the ATS guidelines.18
Statistical analyses
The natural log of J’awNO, CalvNO and FeNO50were found to be
normally distributed hence were used for statistical analysis.
Non-parametric analysis was used for nNO. Least squares
regression models were used to evaluate univariate rela-
tionships between the NO parameters and independent
variables: age, sex, height, weight, FEV1, ambient NO, use of
inhaled corticosteroids and antibiotics. If log transformation
was necessary to achieve normal distribution, log trans-
formed data were used in the model. Linear regression
analysis and a standard backwards model selection process
were used in order to assess relationships between theseNO E+ 743 
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Figure 1 Example of the two-compartment mathematical
technique used to estimate bronchial and alveolar contributions
to FeNO. FeNOwasmeasured atmultiple expiratory flow-rates (50,
100, 200 and 250ml/s). The gradient and intercept of a regression
line between NO elimination (V’NO) and flow-rate (V’E) are
recorded as CalvNO (ppb) and J’awNO (pl/s), respectively.variables and NO parameters and to identify confounding
variables. Analysis of Variance (ANOVA) was used to compare
the geometric mean of J’awNO, CalvNO and FeNO50 between
respiratory disease groups. FeNO50 and subject demographics
were also compared between groups using the ANOVA. Nasal
NO was compared between groups using the KruskaleWallis
test. Confounding variables were adjusted for during the
analyses. A statistical significance level of 0.05 was used
throughout. The data were evaluated using statistical anal-
ysis software SPSS version 19.0.0 (IBM, USA).
Results
There were no differences seen in the demographics of
children in the different respiratory groups apart from
lower weight in those with CF compared to healthy controls
(Table 1).
All NO measurements were completed by the partici-
pants apart from one child with PCD who was unable to
perform the multiple-flow FeNO protocol and three with
asthma who were unable to perform nNO measurements
due to nasal obstruction.
Primary ciliary dyskinesia
As expected nNO was significantly lower in children with
PCD compared to healthy control children (median (inter-
quartile range) 27 (16e76) ppb vs. 772 (690e886) ppb,
p < 0.001) (Table 2 & Fig. 2a). Both bronchial and alveolar
NO were significantly lower in children with PCD compared
to healthy controls (mean (SD) 264 (209) pl/s vs. 720 (514)
pl/s, p Z 0.024, and 1.7 (0.8) ppb vs. 3.5 (1.3) ppb,
p Z 0.001, respectively) (Table 2 & Fig. 2c and d). FeNO50
was also lower in children with PCD, but not with signifi-
cance (mean (SD) 8.8 (7.3) ppb vs. 16.7 (10.8) ppb,
p Z 0.062) (Table 2 & Fig. 2b).
Cystic fibrosis
There was no significant difference in nNO, FeNO50 or
bronchial NO between children with CF and healthy
controls (Table 2, Fig. 2aec). However, alveolar NO was
significantly lower in children with CF (2.5 (1.2) ppb vs. 3.5
(1.3) ppb, p Z 0.001) (Table 2 & Fig. 2d).
Asthma
There was no significant difference in nNO, FeNO50 or
alveolar NO between asthma and healthy controls (Table 2,
Fig. 2a, b and d). However, bronchial NO was significantly
higher in asthmatics (2100 (1935) pl/s v 720 (514) pl/s,
p Z 0.045) (Table 2 & Fig. 2c).
Relationships between NO parameters and
independent variables
There was no significant relationship between parameters
NO and FEV1, FVC or FEF25e75. Ambient NO was 6.0 (7.9)
ppb (mean (SD)) and no relationship was seen between this
and any other NO parameters.
Table 1 Demographics in subjects with primary ciliary dyskinesia, cystic fibrosis and asthma compared with healthy controls
(* indicates p < 0.05) (data presented as mean (SD) unless stated).
Characteristic Group
Healthy
controls
PCD CF Asthma
Number of participants 18 14 12 18
Males (n) (%) 10 (56) 6 (46) 6 (50) 6 (33)
Age (years) 14.1 (2.3) 12.8 (3.9) 11.7 (3.1) 13.5(3.5)
Height (cm) 161 (14) 155 (23) 145 (17) 154 (17)
Weight (kg) 63 (24) 48 (21) 39 (12)* 52 (19)
FEV1 (z-score) e 0.89 (1.00) 1.15 (1.2) 0.35 (1.39)
FVC (z-score) e 0.76 (1.64) 0.60 (0.94) 0.28 (1.10)
FEF25e75 (z-score) e 1.39 (1.13) 1.98 (1.05) 1.39 (1.13)
Inhaled corticosteroids (n) (%) 0 3 (21) 4 (33) 17 (94)
Antibiotics (n) (%) 0 9 (69) 11 (92) 0 (0)
P. aeruginosa (n) (%) e 0 (0) 1 (8) e
Other microorganisms (n) (%) e 5 (38) 3(25) e
Data unavailable.
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The two-compartment model has been validated in an over
20 studies across different respiratory disease groups and
carries the advantage over standard FeNO measurements in
allowing assessment of NO biosynthesis specifically from the
bronchial and alveolar compartments of the lung.8,14,15,19e22
To our knowledge, this is the first study directly comparing
these parameters in PCD, CF, asthma and healthy subjects
within the same study thereby negating issues of methodo-
logical variation between studies when comparing these
different respiratory disease groups.
In our population of children we have demonstrated that
both alveolar and bronchial NO levels are reduced in PCD
while only alveolar levels are reduced in CF and in asthma
bronchial NO levels are raised.Upper airway nitric oxide levels
As previously reported, we found nasal NO levels to be
extremely low in PCD and reduced in CF compared to
healthy and asthmatic children.11,23Table 2 Nitric oxide parameters in subjects with primary ciliary
controls (* & ** indicate p < 0.05 & p < 0.001 respectively) (data
Nitric oxide
parameter
Group
Healthy controls PCD
nNO (ppb)a 772 (690e886) 27 (16e76
FeNO50 (ppb) 16.7 (10.8) 8.8 (7.3)
b,
J’awNO (pl/s) 720 (514) 264 (209)*
b
CalvNO (ppb) 3.5 (1.3) 1.7 (0.8)**
a Median (IQR).
b Adjusted for weight.
c n Z 15 as 3 patients unable to perform nNO test.
d n Z 13 as 1 patient unable to perform FeNO tests.Lower airway nitric oxide levels in primary ciliary
dyskinesia
Our data do not support the study hypothesis that low
levels of airway NO in PCD are due to NOS activity requiring
normal ciliary function.12,13 Also opposing the hypothesis,
different PCD phenotypes including static and hyper-
frequent, had similarly low levels of NO. Instead our find-
ings point to a more generalized mechanism that is not
localized to a specific lung compartment. There are
a number of proposed mechanisms for this including: 1)
reduced biosynthesis of NO due to reduced NOS activity11;
or 2) increased NO breakdown to its metabolites.11
Three studies have utilized this two-compartment model
to assess bronchial and alveolar NO concentrations in
PCD.13e15 Consistent with our findings, all three studies
demonstrated low bronchial NO in PCD patients compared
to controls however only Mahut et al. also found low alve-
olar NO.13e15 Of the other two studies that found equiva-
lent alveolar NO levels between PCD and controls, the work
by Shoemark et al. was undertaken in adults.13 Interestingly
when we compared our adult healthy control group
(assessed to optimize the methods) to our PCD groupdyskinesia, cystic fibrosis and asthma compared with healthy
presented as mean (SD) unless stated).
Cystic fibrosis Asthma
)** 501 (450e608) 769 (560e1124)c
d 14.4 (11.2)b 43.4 (41.2)b
,d 519(495)b 2100 (1935)*b
d 2.5 (1.2)* 5.4 (3.5)
Figure 2 (aed) - Box and whisker plot comparisons of (a) nasal nitric oxide concentration (nNO); (b) fractional exhaled nitric
oxide concentration at 50 ml/s ðFeNO50 Þ; (c) bronchial nitric oxide flux (J’awNO) and (d) alveolar nitric oxide concentration (CalvNO)
in 18 healthy controls, 14 primary ciliary dyskinesia (PCD), 12 cystic fibrosis (CF) and 15 asthma patients. The box represents the
interquartile range intersected by the median. The whiskers represent the range of data. Nasal NO is significantly lower in PCD
compared to healthy subjects. J’awNO is significantly lower in PCD patients and higher in asthma patients compared to healthy
controls. CalvNO is significantly lower in PCD and CF patients compared to healthy controls. (ppb, parts per billion; pl/s, picolitres
per second).
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alveolar NO levels. Paraskakis et al. also found comparable
levels of alveolar NO between PCD and controls.14 However
63% of their PCD group were taking inhaled corticosteroids
(ICS) as compared to only 23% of our PCD population and we
speculate that a higher rate of asthma co-morbidity might
account for the differences in alveolar NO between studies.
There may be other differences between the study pop-
ulations such as concurrent respiratory infection.
Lower airway nitric oxide levels in asthma
There is a large literature on the potential role of FeNO in
the pathophysiology and management of
asthma.7,20,22,24e26 It has generally been found that high
FeNO levels are seen in asthma, particularly in under-
treated asthmatics, and that this is reduced with ICS.26
This has been demonstrated to originate from the bron-
chial region whilst alveolar NO remains relatively normal
and this is consistent with our data.27,28 A recent Cochrane
review concluded that FeNO-guided steroid therapy in
asthma should not be recommended.25 However it has been
suggested that bronchial NO might be more sensitive than
FeNO to monitor response to ICS therapy and that these
parameters may also be of benefit for disease
phenotyping.19,24Lower airway nitric oxide levels in cystic fibrosis
Consistent with two previous studies we found that
bronchial NO in CF was similar to healthy children.21,29 We
found that alveolar NO was significantly lower in our CF
group, consistent with the original work in the area by
Shin et al. however contrary to data from Suri et al. who
found it to be elevated.21,29 We note that there were
a number of differences in the clinical characteristics of
their CF group to ours, with 50% taking ICS and 23%
growing Pseudomonas aeruginosa (33% and 8% respec-
tively in our CF group).21 Nevertheless, as with the PCD
group, the differences between studies may reflect other
more complex mechanisms not captured in the available
clinical data.
Our findings in the CF group, in contrast to the asthma
group and consistent with general opinion, suggest that CF
is mainly a disease of the peripheral airway. Given the anti-
microbial properties of NO, the low alveolar NO levels
might contribute to the chronic recurrent bacterial infec-
tions seen in CF.30 However, alternatively, chronic periph-
eral lung infection with denitrifying bacteria might lead to
increase NO breakdown and hence the low alveolar NO
levels and further work in this area is required.
Despite its advantages, the two-compartment model
is an idealised representation of pulmonary anatomy and
Nitric oxide in PCD, CF and asthma 385function and has intrinsic limitations. Notably, it fails to
account for axial molecular diffusion of bronchial NO
back into the alveolar region, which may lead to
a spurious rise in alveolar NO and decreased bronchial
NO estimates.31e33 Nevertheless, our understanding of
pulmonary NO exchange is in evolution and the impor-
tance of heterogeneous ventilation and inflammation
have yet to be confirmed.34,35 Larger numbers of
subjects would have been of benefit but due to the
rarity of PCD, full validation will require multi-centre
collaboration The numbers we have investigated are in
keeping with previously reported studies and we
included all eligible children with PCD in our clinic.
FeNO was measured according to ATS/ERS guidelines to
ensure accuracy and repeatability of readings.17 FeNO is
non-invasive, acceptable to patients and highly repro-
ducible.17 Contamination of FeNO with nNO was avoided by
exhalation against a minimum mouthpiece pressure of
5 cm H20.
17,36 This process causes velum closure has been
validated by nasal CO2 measurement and nasal argon
insufflation studies.36,37 However given that nNO levels
are almost 40 times greater than FeNO50 in our healthy
children, even small amounts of contamination from the
nasal cavity would lead to significant changes in FeNO. The
NIOX Flex analyser enables inhalation of NO-free air to
control for the effect of ambient NO concentration.
Furthermore a study in 1005 children found that ambient
NO did not affect FeNO when measured according to ATS/
ERS guidelines.38 Similarly we found no relationship
between ambient NO and NO parameters. Measures were
taken to control for non-disease-related factors that may
influence FeNO with groups being age and sexed
matched.17
Due to the significant variance of bronchial and alveolar
NO levels within disease groups these parameters will have
a limited role in aiding the diagnosis of these respiratory
conditions. To date there is little published data on their
use in monitoring disease progression and the benefit of
therapeutic interventions, however the limited work
available in asthma has promise.19,24 In CF the standard
practice of monitoring spirometry in what is a disease of the
peripheral airways is widely considered to be inadequate.
While there is increasing literature on the benefit of lung
clearance index in monitoring CF disease progression its
availability in the clinical setting in presently limited.39e42
The potential benefit of using alveolar NO, a non-invasive
risk-free investigation, in this role might warrant further
investigation.Conclusion
Our findings do not support the hypothesis that NOS and
ciliary function are coupled, instead suggesting a more
generalised mechanism for the low levels of NO seen in PCD.
In our population alveolar NO levels are abnormal in CF and
bronchial NO levels in asthma corroborating evidence that
these are diseases of the lung peripheries and bronchi
respectively. While the use of these NO parameters are
unlikely to aid the diagnosis of respiratory disease longitu-
dinal studies may find benefit in their use in monitoring
therapeutic interventions and disease progression.Acknowledgements
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